The present invention relates to compounds of the formula I,
wherein A, Y, Z, R
20
to R
22
and R
50
have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA
1
receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
本发明涉及公式I的化合物,其中A、Y、Z、R20至
R22和R50具有所述权利要求中所示的含义,它们是有价值的药物活性化合物。具体来说,它们是内皮分化
基因受体2(Edg-2,EDG2)的
抑制剂,该受体被
溶血磷脂酸(LPA)激活,也称为LPA1受体,并且对于治疗动脉粥样硬化、心肌梗死和心力衰竭等疾病有用。本发明还涉及公式I化合物的制备方法、它们的用途以及包含它们的药物组合物。